References (continued)

21. Kumar JD, Holmberg C, Kandola S, et al. Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells. PLoS One. 2014;9(7): e104877.

22. Wang C, Wu WK, Liu X, et al. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides. 2014;51:131–138.

23. Yamaguchi Y, Du XY, Zhao L, Morser J, Leung LL. Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem. 2011;286(45):39510–39519.

24. Tümmler C, Snapkov I, Wickström M, et al. Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo. Oncotarget. 2017;8(56):95135–95151.

25. Pachynski RK, Zabel BA, Kohrt HE, et al. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med. 2012;209(8):1427–1435.

26. Imai K, Takai K, Hanai T, et al. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma. Int J Mol Sci. 2014;15(7):11294–11306.

27. Zhao S, Li C, Ye Y-Bin, Peng F, Chen Q. Expression of chemerin correlates with a favorable prognosis in patients with non-small cell lung cancer. Lab Med. 2011;42(9):553–557.

28. Roh SG, Song SH, Choi KC, et al. Chemerin–a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362(4):1013–1018.

29. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. 2010;391(4):1762–1768.

30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–410.

31. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v8–v30.

32. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21(11):660–667.

33. Ernst MC, Issa M, Goralski KB, Sinal CJ. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology. 2010;151(5):1998–2007.

34. Landgraf K, Friebe D, Ullrich T, et al. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab. 2012;97(4):E556–E564.

35. Kulig P, Kantyka T, Zabel BA, et al. Regulation of chemerin chemoattractant and antibacterial activity by human cysteine cathepsins. J Immunol. 2011;187(3):1403–1410.

36. Schultz S, Saalbach A, Heiker JT, et al. Proteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement. Biochem J. 2013;452(2):271–280.

37. Berg V, Sveinbjornsson B, Bendiksen S, Brox J, Meknas K, Figenschau Y. Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin (21-157). Arthritis Res Ther. 2010;12(6):R228.

38. Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14(3):245–262.

39. Parolini S, Santoro A, Marcenaro E, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007;109(9):3625–3632.

40. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005;175(1):487–493.

41. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.

42. Arias JI, Aller MA, Arias J. Cancer cell: using inflammation to invade the host. Mol Cancer. 2007;6:29.

43. Boyle ST, Kochetkova M. Breast cancer stem cells and the immune system: promotion, evasion and therapy. J Mammary Gland Biol Neoplasia. 2014;19(2):203–211.

44. Jeong YJ, Hk O, Park SH, Bong JG. Association between inflammation and cancer stem cell phenotype in breast cancer. 2018;15(2):2380–2386.

45. Leroith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127–137.

46. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015;2015:538019–24.

47. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Target. 2010;11(9):1133–1146.

48. Soria G, Ofri-Shahak M, Haas I, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011;11:130.

49. Somja J, Demoulin S, Roncarati P, et al. Dendritic cells in Barrett’s esophagus carcinogenesis: an inadequate microenvironment for antitumor immunity? Am J Pathol. 20132013;182036(6):2168–2179.

50. Kumar JD, Kandola S, Tiszlavicz L, Reisz Z, Dockray GJ, Varro A. The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells. Br J Cancer. 2016;114(10):1152–1159.

51. Xu CH, Yang Y, Wang YC, Yan J, Qian LH. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer. Oncotarget. 2017;8(14):22483–22489.

52. Bozaoglu K, Curran JE, Stocker CJ, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95(5):2476–2485.

53. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13(2):279–292.

54. Perrier S, Caldefie-Chézet F, Vasson MP. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett. 2009;583(2):259–265.

55. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-α stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis. 2013;9(2):306–314.

Source: Breast Cancer: Targets and Therapy.
Originally published October 23, 2018.